Immunosuppression and Cancer: The Ciclosporin Case-Reference-Cited by-同舟云学术

Immunosuppression and Cancer: The Ciclosporin Case

Published:1992-01 Issue:2 Volume:15 Page:95-115
ISSN:0148-0545
Container-title:Drug and Chemical Toxicology
language:en
Short-container-title:Drug and Chemical Toxicology

Author:

Ryffel Bernhard¹,Mihatsch Michael J.²,Fisher Gerald L.³

Affiliation:

1. Sandoz Pharma, Drug Safety, CH-4003, Basel

2. Institute of Pathology, University, CH-4003, Basel

3. Sandoz Research Institute, East Hanover, NJ, USA

Publisher

Informa UK Limited

Subject

Chemical Health and Safety,Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health,Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.3109/01480549209032293

Reference116 articles.

1. CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERS

2. LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN THERAPY

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in Kaposi’s Sarcoma Morbidity: A Retrospective Cohort Study of Heart and Lung Transplant Recipients;Acta Dermato Venereologica;2021

2. Production of Cyclosporine A by Submerged Fermentation;Fungal Metabolites;2017

3. Production of Cyclosporine A by Submerged Fermentation;Fungal Metabolites;2015

4. Drug Development in Solid Organ Transplantation and the Approval Process for Transplant Immunosuppressants;Textbook of Organ Transplantation;2014-07-25

5. Lymphohematopoietic cancers induced by chemicals and other agents and their implications for risk evaluation: An overview;Mutation Research/Reviews in Mutation Research;2014-07